# A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

> **NCT03946800** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 61 (actual)

## Conditions studied

- Solid Tumors
- Cancer

## Interventions

- **BIOLOGICAL:** MEDI1191
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT03946800
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-08
- **Primary completion:** 2023-08-24
- **Final completion:** 2023-08-24
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03946800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03946800, "A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT03946800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*